397 studies found for:    Open Studies | Interventional Studies | melanoma
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | Interventional Studies | melanoma
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
2 Recruiting Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIB Melanoma (Locally Advanced);   Stage IIC Melanoma (Locally Advanced);   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma (Limited, Resectable)
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
3 Recruiting INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Conditions: Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Drug: IDO1 inhibitor INCB024360;   Biological: MELITAC 12.1 peptide vaccine;   Other: laboratory biomarker analysis
4 Recruiting Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab
5 Recruiting LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma;   BRAF Mutant Melanoma
Intervention: Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
6 Recruiting Molecularly Targeted Therapy in Treating Patients With Melanoma That is Metastatic or Cannot be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Other: cytology specimen collection procedure;   Drug: molecularly targeted therapy;   Procedure: therapeutic procedure;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
7 Recruiting Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma
Intervention: Drug: Pazopanib and Paclitaxel
8 Not yet recruiting Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Conditions: Stages III Skin Melanoma;   Stages II Skin Melanoma;   Stage IB Skin Melanoma
Interventions: Drug: Propranolol hydrochloride;   Drug: Placebo pill
9 Not yet recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
10 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: riluzole;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Recruiting Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Biological: therapeutic tumor infiltrating lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis
13 Recruiting Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: cabozantinib-s-malate;   Drug: temozolomide;   Drug: dacarbazine;   Other: laboratory biomarker analysis
14 Recruiting Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: axitinib;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: 3'-deoxy-3'-[18F]fluorothymidine;   Procedure: positron emission tomography
15 Recruiting Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IA Melanoma;   Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: fluorescein sodium injection;   Procedure: diagnostic microscopy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
16 Recruiting Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
Conditions: Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Intervention: Biological: recombinant hsp110-gp100 chaperone complex vaccine
17 Not yet recruiting High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: ipilimumab;   Other: laboratory biomarker analysis
18 Recruiting Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: Montanide ISA 51 VG;   Biological: MART-1 antigen;   Other: laboratory biomarker analysis;   Biological: Gag:267-274 peptide vaccine;   Drug: resiquimod
19 Recruiting Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: dabrafenib;   Drug: trametinib;   Drug: Hsp90 inhibitor AT13387;   Other: pharmacological study;   Other: laboratory biomarker analysis
20 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Carcinoma of Unknown Primary;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: recombinant flt3 ligand;   Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Biological: neoantigen-based melanoma-poly-ICLC vaccine;   Other: laboratory biomarker analysis;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years